Skip to main content
Premium Trial:

Request an Annual Quote

Illumina TruSight Tumor 170

Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only.